Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Fish and Richardson
Dow
Julphar
Farmers Insurance
Harvard Business School
Medtronic
McKinsey
Teva

Generated: May 28, 2018

DrugPatentWatch Database Preview

PERMAX Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Permax, and when can generic versions of Permax launch?

Permax is a drug marketed by Valeant Pharm Intl and is included in one NDA.

The generic ingredient in PERMAX is pergolide mesylate. There are four drug master file entries for this compound. Additional details are available on the pergolide mesylate profile page.
Summary for PERMAX
Drug patent expirations by year for PERMAX
Medical Subject Heading (MeSH) Categories for PERMAX
Synonyms for PERMAX
(2R,4R,7R)-4-[(METHYLSULFANYL)METHYL]-6-PROPYL-6,11-DIAZATETRACYCLO[7.6.1.0(2),?.0(1)(2),(1)?]HEXADECA-1(15),9,12(16),13-TETRAENE; METHANESULFONIC ACID
(6aR,9R,10aR)-9-((methylthio)methyl)-7-propyl-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline methanesulfonate
(6aR,9R,10aR)-9-(methylsulfanylmethyl)-7-propyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline;methanesulfonic acid
(8b)-8-[(methylsulfanyl)methyl]-6-propylergoline methanesulfonate
(8beta)-8-[(methylsulfanyl)methyl]-6-propylergolin-6-ium methanesulfonate
(8beta)-8-[(methylsulfanyl)methyl]-6-propylergoline methanesulfonate
104P232
55B9HQY616
66104-22-1 (Parent)
66104-23-2
8-.beta.-[(Methylthio)methyl]-6-propylergoline methanesulfonate
8-[(Methylthio)methyl]-6-propylergoline methanesulfonate
8-beta-((Methylthio)methyl)-6-propylergoline methanesulfonate
8-beta-((Methylthio)methyl)-6-propylergoline monomethane sulfonate
8|A-[(Methylthio)methyl]-6-propylergoline methanesulfonate salt
8beta-((Methylthio)methyl)-6-propylergoline monomethanesulfonate
8beta-[(Methylthio)methyl]-6-propylergoline methanesulfonate salt
AC-6874
AC1L2IT6
AKOS015896681
AN-1514
C19H26N2S.CH4O3S
CAS-66104-23-2
CCG-39478
Celance
CHEBI:8021
CHEMBL1275
CPD000058504
CS-2629
CTK8G2324
D00502
DSSTox_CID_20583
DSSTox_GSID_40583
DSSTox_RID_77029
DTXSID6040583
Ergoline, (8.beta.)-, monomethanesulfonate
Ergoline, 8-((methylthio)methyl)-6-propyl-, monomethanesulfonate, (8beta)-
Ergoline, 8-beta-((methylthio)methyl)-6-propyl-, methanesulfonate (1:1)
Ergoline, methanesulfonate (1:1)
EU-0100984
EX-A1334
HMS1568L12
HMS1922O13
HMS2052H09
HMS2093C05
HMS2095L12
HMS2231F08
HMS3263E09
HMS501G04
HY-13720A
I06-2189
LP00984
LS-64480
LY 127809
LY-141-B
LY127809
MFCD00153859
MLS000069837
MLS001148155
MLS001424320
MLS002222236
MolPort-003-666-477
NC00428
NCGC00017366-04
NCGC00017366-08
NCGC00094284-01
NCGC00094284-02
NCGC00094284-03
NCGC00261669-01
Nopar
NSC-319773
NSC-758442
NSC319773
NSC758442
Opera_ID_186
P 8828
Parkotil
Pergolide (mesylate)
Pergolide mehanesulfonate
Pergolide mesilate
Pergolide mesilate (JAN)
Pergolide mesilate, European Pharmacopoeia (EP) Reference Standard
PERGOLIDE MESYLATE
Pergolide mesylate (USP)
Pergolide mesylate [USAN:USP]
Pergolide mesylate [USAN]
PERGOLIDE MESYLATE SALT
Pergolide mesylate salt, >=98%, solid
Pergolide mesylate, United States Pharmacopeia (USP) Reference Standard
Pergolide Methanesulfonate
Pergolide methanesulfonate salt
pergolide monomesylate
pergolide monomethanesulfonate
Pergolidemesylatesalt
Pharken
Pharmakon1600-01503269
PL065985
Prestwick_652
Q-201548
s4000
SCHEMBL26920
SMR000058504
SPECTRUM1503269
Tox21_110820
Tox21_110820_1
Tox21_500984
UNII-55B9HQY616

US Patents and Regulatory Information for PERMAX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Valeant Pharm Intl PERMAX pergolide mesylate TABLET;ORAL 019385-001 Dec 30, 1988 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Valeant Pharm Intl PERMAX pergolide mesylate TABLET;ORAL 019385-002 Dec 30, 1988 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Valeant Pharm Intl PERMAX pergolide mesylate TABLET;ORAL 019385-003 Dec 30, 1988 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Expired US Patents for PERMAX

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Valeant Pharm Intl PERMAX pergolide mesylate TABLET;ORAL 019385-003 Dec 30, 1988 ➤ Sign Up ➤ Sign Up
Valeant Pharm Intl PERMAX pergolide mesylate TABLET;ORAL 019385-001 Dec 30, 1988 ➤ Sign Up ➤ Sign Up
Valeant Pharm Intl PERMAX pergolide mesylate TABLET;ORAL 019385-001 Dec 30, 1988 ➤ Sign Up ➤ Sign Up
Valeant Pharm Intl PERMAX pergolide mesylate TABLET;ORAL 019385-003 Dec 30, 1988 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Dow
Accenture
Cerilliant
UBS
Covington
Medtronic
Fuji
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.